When the world shut down, Roche went all-in and carried on its research programs

It was no easy decision to keep clinical trials going last spring, when the Covid-19 pandemic escalated, but Roche quickly decided that it would keep as much research going as it could, says research executive. This is now paying off.

Roche SVP, Global Head Oncology, Pharma Research and Early Development Dominik Ruettinger. | Photo: Roche / PR

Even though pharmaceutical companies, overall, have not been hit as hard by the Covid-19 pandemic as most other industries, pharmaceutical and biotech companies have been especially challenged in one particular area, which is that of clinical research.

Once the pandemic really started having an impact, many companies were at a loss for what to do. One of them was Roche, according to Dominik Ruettinger, the pharmaceutical firm's senior vice president and global head of Oncology, Pharma Research and Early Development (pRed).

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs